AstraZeneca has entered an exclusive licence agreement with Alteogen involving the latter’s ALT-B4 platform technology.

Curevo has set its sights on competing with GSK’s shingles vaccine dominance by securing $110m and securing a former executive from the UK big pharma to advance its candidate amezosvatein.

Curevo has set its sights on competing with GSK’s shingles vaccine dominance by securing $110m and securing a former executive from the UK big pharma to advance its candidate amezosvatein.

Health Canada has granted approval for Biogen’s Skyclarys to treat Friedreich’s ataxia (FA) in individuals aged 16 years and above.

Experts at the 2025 Clinical Trial Supply New England conference will discuss strategies for optimising clinical supply ...

The two simultaneous Incyte trials in HS saw more than 40% of patients on povorcitinib achieving a clinical response.

The use of AI in drug discovery and development has been recognised, explored, and implemented throughout the last decade, with a notable acceleration in recent years.

Taiho Pharmaceutical has agreed to acquire Swiss-based antibody-drug-conjugate (ADC) specialist Araris Biotech for up to ...

Azurity Pharmaceuticals has acquired Covis Group from existing investors, making the latter a wholly owned subsidiary.

Experts debate whether European manufacturers are preferring domestic operations as the continent competes with Asia and the ...

While China has become a key country for global clinical trials, navigating regulatory complexities and ensuring data integrity requires expertise and in-country support services.

The EC has granted expanded approval to BMS' Breyanzi, to treat adults with relapsed or refractory follicular lymphoma (FL).